Peptide Rule Changes in 2026: Legal Risks for Athletes

Two rulebooks, two kinds of consequence

Athletes who use peptides answer to two separate systems, and each one punishes something different. Anti-doping rules, written by WADA and enforced by agencies such as USADA and by sport federations, decide whether you can compete. US drug law, enforced by the FDA and the Department of Justice, decides whether a product can legally be sold or imported.

The two don't line up neatly. Semaglutide sold as a "research chemical" has drawn FDA warning letters, yet WADA doesn't prohibit it. BPC-157 can end a tested athlete's career, but none of the 2026 federal cases we found targeted a buyer for personal use.

System	What it controls	Main consequence for athletes	Main consequence for sellers
WADA Code and Prohibited List	What's in an athlete's sample or possession	Ineligibility (commonly 2 or 4 years), lost results	Online vendors generally aren't bound by the Code
Federal drug law (FDA, DOJ, CBP)	Sale and import of unapproved drugs	Seized packages; buyers weren't the target of the 2026 cases we found	Warning letters, seizure, injunction, prison

How the same changes affect access is covered in our overview of regulatory changes in sport.

What WADA's 2026 and 2027 lists say

The 2026 Prohibited List has applied since January 1, 2026. Nearly every peptide discussed in performance circles is on it, by name or by class, and all of the following are prohibited at all times (in and out of competition):

BPC-157: named in S0, non-approved substances.
TB-500 and thymosin beta-4: S2.3, growth factors. They are not in S0, despite what some older guides say.
CJC-1295, sermorelin and tesamorelin: S2.2.4, as GHRH analogues.
Ipamorelin, ibutamoren (MK-677), hexarelin and GHRP-1 to GHRP-6: S2.2.4, as growth hormone secretagogues and GHRPs.
IGF-1 and its analogues, and mechano growth factors: S2.3.

Semaglutide and tirzepatide are the exception. As of October 2026 they aren't prohibited, and USADA's advisory says they stay in WADA's Monitoring Program for 2027, which means labs track them without sanctions.

The 2027 List takes effect on January 1, 2027. According to USADA's athlete advisory, its S0 definition now names "peptides" in general among the examples of non-approved substances. USADA also warns that peptides sold under new names or slang may not appear in Global DRO, its lookup tool. The practical reading: an unlisted peptide that no health authority has approved for human use should be treated as prohibited.

One edge case is unresolved. Elamipretide (SS-31) won FDA accelerated approval as Forzinity in September 2025, so it no longer fits S0's "no current approval" test, and the list doesn't name it elsewhere. We couldn't confirm how WADA now classifies it.

How anti-doping sanctions work

Two rules in the World Anti-Doping Code shape the consequences. The figures below come from the 2021 Code, which applies until the 2027 Code takes effect on January 1, 2027; we haven't checked whether the new Code changes them.

The first is strict liability. An athlete is responsible for whatever is found in their sample, whether or not they meant to take it. That becomes important with gray-market products, because a contaminated vial counts against the athlete, not the seller.

The second is the split between Specified and non-Specified substances, which sets the default ban under Article 10.2:

S0 substances, including BPC-157, are Specified. The default ban is 2 years, rising to 4 if the anti-doping organization shows the use was intentional.
S2 substances, including TB-500, CJC-1295, ipamorelin and the GHRPs, are non-Specified. The default is 4 years unless the athlete shows the violation wasn't intentional.

Someone who injected a peptide on purpose will find "not intentional" hard to argue, so 4 years is the realistic figure for the S2 compounds.

A positive test isn't the only way to commit a violation. Under Article 2.6, possessing a substance that's prohibited out of competition is a violation in itself, unless the athlete has a Therapeutic Use Exemption (TUE) or another accepted justification. Because every peptide listed above is banned at all times, a vial found during an investigation can be enough.

A prescription isn't a TUE

Some prohibited peptides are easier to get through medical channels than they used to be. Sermorelin is the clearest example. FDA determined in 2013 that its brand-name version, Geref, wasn't withdrawn for safety or effectiveness reasons, which is why US pharmacies can still compound it with a prescription.

A prescription doesn't change sport status. Sermorelin sits in S2.2.4 whether it comes from a licensed pharmacy or a research-chemical site, and a tested athlete still needs an approved TUE before using it. Our sermorelin profile covers what the evidence shows about the compound itself.

What changed at FDA in 2026

An earlier version of this page said ipamorelin and CJC-1295 were in FDA's 503A Category 2. That's out of date. Both now sit in FDA's "nominated but withdrawn" table, and neither appears on the 503A category list as updated May 14, 2026. Ipamorelin acetate remains in Category 2 under the separate 503B policy for outsourcing facilities, where FDA cites serious adverse events, including death, in an intravenous study.

The larger 2026 story is a partial reversal on other peptides, summarized by LumaLex Law:

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said most of the roughly 19 restricted peptides should move back toward legal compounding.
In April 2026, FDA took 12 peptides off Category 2, including BPC-157 and TB-500, after their nominators withdrew.
On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee voted, over FDA staff objections, to recommend six of them for the 503A bulks list. BPC-157 and TB-500 each passed 8-6-1.

None of this is self-executing. FDA has to go through notice-and-comment rulemaking before anything is added to the list, and a Federal Register search in early October 2026 showed no proposed rule. Leaving Category 2 doesn't authorize compounding either. Even after listing, a compounded peptide would need a valid prescription and a licensed pharmacy, and LumaLex notes that listing wouldn't legalize research-use-only consumer sales.

For athletes, the compounding debate doesn't touch sport status. WADA names BPC-157 in S0 and TB-500 in S2.3, and compounding access isn't drug approval. Our BPC-157 profile tracks its regulatory history in more detail.

Enforcement against "research use only" sellers

FDA's letters show how little the research-use label protects a seller.

Earlier precedent (February 2024): FDA's letter to US Chem Labs found that "research chemicals only" and "not for human consumption" labels didn't stop its semaglutide and tirzepatide from being unapproved drugs.
March 31, 2026: FDA's letter to Gram Peptides covered retatrutide, tirzepatide and bacteriostatic water. FDA said selling the water alongside injectable peptides showed it was intended for injection, which made the water itself a drug.
August 24, 2026: FDA's letter to Peak Performance Peptides named retatrutide, semaglutide, SS-31, PT-141, tesamorelin and "Bac water" as unapproved new drugs. The cited product copy was hedged research language ("Studied for effects on glycemic control", "Considered in preclinical models"), and FDA still treated it as evidence of intended human use. The letter warned of possible seizure and injunction.

Criminal cases have followed. According to CBS News, on July 30, 2026 a federal judge sentenced Matthew Kawa, owner of Paradigm Peptides, to 70 months in prison after he pleaded guilty to selling unapproved drugs and importing them illegally. Kawa admitted forging lab certificates, and government tests found that products sold as SARMs contained testosterone. CBS described the sentence as a rare criminal penalty for a research-use seller.

Imports are being stopped too. CBP officers in Cincinnati seized about 5,000 mis-manifested peptide shipments from China between December 2025 and March 2026, including retatrutide, semaglutide and MOTS-c.

What this means for a tested athlete

The Paradigm case shows where the two rulebooks meet. Customers bought products labeled as SARMs that tested as testosterone, backed by certificates the owner admitted were forged. Under strict liability, an athlete who used one of those products would face a testosterone violation (S1, anabolic agents) regardless of the label. A certificate of analysis on a seller's website isn't proof of what's in the vial. Our page on the health risks of unregulated peptides covers contamination and counterfeit products in more depth.

On the federal side, the 2026 actions we found were aimed at sellers and smugglers. Buyers face more practical losses: a seized package, a seller that disappears, and little recourse. Paradigm was shut down in March 2024, and CBS reported that look-alike sites have since appeared using similar branding. State laws vary, and nothing here is legal advice.

What to watch next

FDA rulemaking. Whether FDA proposes adding the six PCAC-backed peptides to the 503A bulks list, or moves them to an interim category first. LumaLex reports a second advisory meeting, on GHK-Cu, melanotan II, LL-37, dihexa and PEG-MGF, planned before the end of February 2027.
January 1, 2027. The 2027 Prohibited List and the 2027 World Anti-Doping Code both take effect.
Approved peptides in sport. How WADA treats elamipretide now that it has an approved form.
The scope of warning letters. The 2026 letters we read focused on GLP-1 drugs plus SS-31, PT-141 and tesamorelin. Whether FDA widens that pattern is an open question.